Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

David Sallman, MD, elaborates on the first-in-class anti-CD47 antibody magrolimab

Dr. Sallman, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center, tells us about the first-in-class anti-CD47 antibody magrolimab and why this product may be important in the management of acute myeloid leukemia (AML)

Tags: ASH Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Published: 15 December 2020

Recent Videos: ASH Conference Coverage

video

Radhakrishnan Ramchandren, MD, provides perspective on the safety & efficacy of brentuximab vedotin

Dr. Ramchandren, Chief, Division of Hematology/Oncology, University of Tennessee Medical Center, provides perspective on the safety and efficacy of brentuximab ...

video

Radhakrishnan Ramchandren, MD, offers opinion on the ECHELON-2 trial as presented at ASH 2020

Dr. Ramchandren, Chief, Division of Hematology/Oncology, University of Tennessee Medical Center, discusses the five-year follow-up of the ECHELON-2 study investigating ...

video

Radhakrishnan Ramchandren, MD, elaborates on the five-year follow-up data from ECHELON-1

Dr. Ramchandren, Chief, Division of Hematology/Oncology, University of Tennessee Medical Center, shares details from the five-year follow-up of the ECHELON-1 ...

video

Leslie Popplewell, MD, FACP, on the challenges of delivering CAR T-cell therapy to lymphoma patients

Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, considers the biggest challenges in ...

video

Leslie Popplewell, MD, FACP, on the management of adverse events associated with CAR T-cell therapy

Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, regarding the management of adverse ...

video

Leslie Popplewell, MD, FACP, describes how engineered toxin bodies work as an anti-cancer treatment

Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, describes how engineered toxin bodies ...

video

Leslie Popplewell, MD, FACP, on the future of CAR T-cell therapies in follicular lymphoma

Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, speculates on the future of ...

video

Leslie Popplewell, MD, FACP, discusses the latest treatment trends in follicular lymphoma

Dr. Popplewell, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Hematologist/Oncologist, City of Hope, shares perspective on the latest ...

video

Frederick Locke, MD, shares thoughts on the evolution of bispecific antibodies

Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, shares thoughts on ...

video

Frederick Locke, MD, speculates on the future of CAR T-cell therapies

Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant & Cellular Immunotherapy, Moffitt Cancer Center, offers opinion on ...

Related Videos

video-image

Radhakrishnan Ramchandren, MD, provides perspective on the safety & efficacy of brentuximab vedotin

video-image

Radhakrishnan Ramchandren, MD, offers opinion on the ECHELON-2 trial as presented at ASH 2020

video-image

Radhakrishnan Ramchandren, MD, elaborates on the five-year follow-up data from ECHELON-1

video-image

Leslie Popplewell, MD, FACP, on the challenges of delivering CAR T-cell therapy to lymphoma patients

video-image

Leslie Popplewell, MD, FACP, on the management of adverse events associated with CAR T-cell therapy

video-image

Leslie Popplewell, MD, FACP, describes how engineered toxin bodies work as an anti-cancer treatment

video-image

Leslie Popplewell, MD, FACP, on the future of CAR T-cell therapies in follicular lymphoma

video-image

Leslie Popplewell, MD, FACP, discusses the latest treatment trends in follicular lymphoma

video-image

Frederick Locke, MD, shares thoughts on the evolution of bispecific antibodies

video-image

Frederick Locke, MD, speculates on the future of CAR T-cell therapies

video-image

David Sallman, MD, offers opinion on the most exciting clinical data in AML coming out of ASH 2020

video-image

Frederick Locke, MD, discusses details from the ZUMA-9 clinical study presented at ASH 2020

video-image

David Sallman, MD, offers details regarding the clinical investigation of CYAD-01

video-image

Frederick Locke, MD, offers impressions of the ZUMA-2 study presented at ASH 2020

video-image

Mazyar Shadman, MD, on the investigation of 3rd-generation CAR T-cell therapies targeting CD20

video-image

Frederick Locke, MD, summarizes outcomes from the ZUMA-1 clinical trial presented at ASH 2020

video-image

David Sallman, MD, on what the IDH2 mutation reveals about the prognosis in acute myeloid leukemia

video-image

Mazyar Shadman, MD, on the efficacy & tolerability of zanubrutinib in B-cell malignancies

video-image

Mazyar Shadman, MD, on patients with B-cell malignancies who are intolerant to 1st line ibrutinib

video-image

Chaitra Ujjani, MD, speculates on next steps in the investigation of ibrutinib + venetoclax

video-image

Chaitra Ujjani, MD, regarding the evolving treatment landscape of follicular lymphoma

video-image

Chaitra Ujjani, MD, elaborates on the impact of new therapies in follicular lymphoma

video-image

Chaitra Ujjani, MD, considers the efficacy of ibrutinib + venetoclax in relapsed/refractory FL

video-image

Chaitra Ujjani, MD, regarding the investigation of CLL patients hospitalized with COVID-19

video-image

Lori Leslie, MD, on real-world outcomes in CLL patients receiving ibrutinib or chemoimmunotherapy

video-image

Lori Leslie, MD, discusses the Phase II Global Unity-NHL trial from ASH 2020

video-image

Lori Leslie, MD, considers whether ibrutinib + venetoclax is effective in the management of FL

video-image

Michael Savona, MD, regarding the ASCEMBL study presented at ASH 2020

video-image

David Siegel, MD, PhD, shares details from the APOLLO & CANDOR trial updates presented at ASH '20

video-image

Jennifer Brown, MD, PhD, provides perspective on the side-effect profiles of next-gen BTK inhibitors

video-image

David Siegel, MD, PhD, regarding the early test results of CC-220 presented at ASH 2020

video-image

Jennifer Brown, MD, PhD, on the addition of zanubrutinib to the NCCN Guidelines for CLL

video-image

David Siegel, MD, PhD, elaborates on outcomes from the KarMMa trial

video-image

Jennifer Brown, MD, PhD, offers opinion on how zanubrutinib fits into the CLL treatment landscape

video-image

David Siegel, MD, PhD, regarding bispecific antibodies in the management of relapsed/refractory MM

video-image

Jennifer Brown, MD, PhD, shares outcomes of Arm C of the SEQUOIA trial from ASH 2020

video-image

David Siegel, MD, PhD, summarizes outcomes from the Phase I CRB-402 study presented at ASH 2020

video-image

Jennifer Brown, MD, PhD, considers the unmet needs in patients with CLL or SLL with del(17p)

video-image

Lindsey Roeker, MD, on examining the experience of CLL patients hospitalized with COVID-19

video-image

Anthony Mato, MD, MSCE, examines different treatment approaches to BTK inhibitor intolerance

video-image

Melissa Alsina, MD, considers the role of anti-BCMA CAR-T cell therapy

video-image

Anthony Mato, MD, MSCE, elaborates on outcomes from the BRUIN trial presented at ASH 2020

video-image

Melissa Alsina, MD, shares the long-term follow-up outcomes of the Phase I CRB-402 study

video-image

Anthony Mato, MD, MSCE, shares some of the key findings on the InformCLL Registry from ASH 2020

video-image

Melissa Alsina, MD, offers opinion on anti-BCMA CAR-T cell therapy

video-image

Anthony Mato, MD, MSCE, tells us about the InformCLL Registry

video-image

Julio Chavez, MD, MS, provides perspective on exciting data in NHL coming out of ASH 2020

video-image

Julio Chavez, MD, MS, offers opinion on the significance of BCL10 mutations

video-image

Julio Chavez, MD, MS, considers the most exciting clinical studies of axi-cel in lymphoma

video-image

Julio Chavez, MD, MS, shares outcomes from the ZUMA-5 study presented at ASH 2020

video-image

Othman Al-Sawaf, MD, discusses outcomes from the 4-year follow-up of the CLL14 from ASH '20

video-image

Julio Chavez, MD, MS, discusses the unique mechanism of action of axicabtagene ciloleucel

video-image

Othman Al-Sawaf, MD, on the role of MRD in the management of CLL as a result of data from ASH 2020

video-image

Julio Chavez, MD, MS, regarding the typical treatment algorithms for relapsed/refractory iNHL

video-image

Othman Al-Sawaf, MD, on potential safety concerns associated with venetoclax combinations

video-image

Yi Lin, MD, PhD, shares impressions of the APOLLO study in relapsed/refractory MM from ASH 2020

video-image

Othman Al-Sawaf, MD, regarding the standard of care for first-line treatment of newly diagnosed CLL

video-image

Yi Lin, MD, PhD, on how anti-BCMA CAR-T cell therapy fits into the treatment of RRMM

video-image

Sattva Neelapu, MD, shares highlights in the development of CAR T-cell therapies in lymphoma

video-image

Yi Lin, MD, PhD, offers opinion on anti-BCMA CAR-T cell therapy

video-image

Sattva Neelapu, MD, elaborates on long-term results from the ZUMA-1 trial

video-image

Peter Voorhees, MD, offers opinion on the role of daratumumab as more trial data emerges

video-image

Sattva Neelapu, MD, discusses advancements in the management of CAR T-cell therapy AEs

video-image

Yi Lin, MD, PhD, discusses the unique mechanism of action of ide-cel

video-image

Sattva Neelapu, MD, speculates on the future of first-line CAR T-cell therapy in lymphoma

video-image

Peter Voorhees, MD, on progress with BCMA-targeted therapies and the challenge of relapse

video-image

Sattva Neelapu, MD, discusses details of the ZUMA-12 trial presented at ASH 2020

video-image

Michael Jain, MD, PhD, provides an update on the progress of the ZUMA-11 trial

video-image

Michael Jain, MD, PhD, on what we're learning about 'out of specification' CAR T-cell products

video-image

Michael Jain, MD, PhD, speculates on exciting studies of immunotherapy in lymphoma

video-image

Michael Jain, MD, PhD, discusses the management of CAR T-cell therapy adverse events

video-image

Michael Jain, MD, PhD, on immunotherapy treatment trends in the management of aggressive lymphomas

video-image

Michael Savona, MD, considers the practice-changing potential of the ASCERTAIN study

video-image

Stephen Ansell, MD, PhD, elaborates on treatment considerations in Waldenstrom macroglobulinemia

video-image

Michael Savona, MD, discusses outcomes from the ASCERTAIN trial presented at ASH 2020

video-image

Peter Voorhees, MD, regarding current controversies in the treatment of multiple myeloma

video-image

Michael Savona, MD, elaborates on the role of cytidine deaminase (CDA)

video-image

Stephen Ansell, MD, PhD, elaborates on bridging therapy for lymphoma patients

video-image

Peter Voorhees, MD, discusses some of the current approaches to dealing with daratumumab resistance

video-image

Stephen Ansell, MD, PhD, speculates on promising new treatment combinations in follicular lymphoma

video-image

Peter Voorhees, MD, regarding the treatment landscape in newly diagnosed & relapsed/refractory MM

video-image

Stephen Ansell, MD, PhD, on options for lymphoma patients who are refractory to CAR T-cell treatment

video-image

Stephen Ansell, MD, PhD, describes the landscape of immunotherapy approaches in lymphoma

video-image

Thomas Martin, MD, speculates on the future of the IKEMA study in relapsed multiple myeloma

video-image

Bhavana Bhatnagar, DO, on the design of clinical trials and the representation of minority patients

video-image

Bhavana Bhatnagar, DO, shares key takeaways for clinicians regarding racial disparities in AML

video-image

Thomas Martin, MD, shares thoughts on minimal residual disease as an indicator of response in MM

video-image

Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from ASH 2020

video-image

Thomas Martin, MD, talks safety concerns regarding isatuximab plus carfilzomib and dexamethasone

video-image

Bhavana Bhatnagar, DO, on the significance of examining racial disparities in the treatment of AML

video-image

Thomas Martin, MD, considers the significance of the IKEMA study

video-image

Bhavana Bhatnagar, DO, on unexpected findings from a study of racial disparities in treatment of AML

video-image

Thomas Martin, MD, discusses outcomes from the Phase III IKEMA study in relapsed MM from ASH 2020

video-image

Andrew Zelenetz, MD, provides the clinical progress and outcomes to date with the BOVen trial in CLL

video-image

Jorge Cortes, MD, on the evolution of CAR-T cell therapies in hematologic malignancies management

video-image

Jorge Cortes, MD, discusses the take home message from the OPTIC study in CML patients for HCPs

video-image

Jorge Cortes, MD, provides thoughts on what the impact of the OPTIC study will be on CML patients

video-image

Jorge Cortes, MD, tells us about the OPTIC study, a phase 2 investigation of ponatinib in CML